Several studies have proven oseltamivir to be efficient in reducing influenza viral titer and symptom intensity. However, the usefulness of oseltamivir can be compromised by the emergence and spread o
Note: Results for each analysis were considered statistically significant if p<0.001. BL: baseline; FU: follow-up; C-SVR: co-infected sustained virologic responders; C-NR: co-infected non-responders;
SARS-CoV-2 infected animals and controls were treated with antiviral peptides Overall design: Animals were untreated or pretreated with either dimer or PEG-24 lipopeptide, followed by SARS-2 infection
